The differential effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on seizure frequency in patients with drug-resistant epilepsy — A randomized, double-blind, placebo-controlled trial

Published:August 28, 2018DOI:


      • Eicosapentaenoic acid (EPA) and docosahexaenoic acid (EPA), are known to modify neuronal function and excitability.
      • Treatment with DHA or EPA reduces seizure rate in patients with Drug Resistant Epilepsy (DRE) by 39% and 42% respectively.
      • DHA and EPA reduces the number of seizure-free days. DHA and EPA had a comparable therapeutic effects in patients with DRE.



      The omega-3 (n3) fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are known to play an important role in maintenance and modulation of neuronal functions. There is evidence that omega-3 fatty acids may have anticonvulsant effects. The effect of DHA and EPA on seizure rate in patients with drug-resistant epilepsy (DRE) was investigated.


      A double-blind, randomized, placebo-controlled clinical trial included ninety-nine (n = 99) subjects with DRE, aged 5–16 years (n = 85) and 17–45 years (n = 14). After randomization, subjects were given two, four, or six capsules per day of DHA (417.8 mg DHA and 50.8 mg EPA/capsule, n = 33), EPA (385.6 mg EPA and 81.2 mg DHA/capsule, n = 33), or placebo (high oleic acid sunflower oil, n = 33) for one year. The primary endpoint was the effect of treatment on rate of seizure. Random-effects negative binomial regression models were fitted to model the patients' total count of seizures per month. The treatment effects on seizure incidence rate ratio (IRR) were tested after controlling for the covariate effects of gender, age, rate of seizure per week at enrollment, type of seizure, and number of antiepileptic drug (AED) combinations used at enrollment.


      Fifty-nine subjects (n = 59) completed the study (59.6%). The average number of seizures per month were 9.7 ± 1.2 in the EPA group, 11.7 ± 1.5 in the DHA group, and 16.6 ± 1.5 in the placebo group. Age, gender, and seizure-type adjusted seizure IRRs of the EPA and DHA groups compared with the placebo group were 0.61 (CI = 0.42–0.88, p = 0.008, 42% reduction) and 0.67 (CI = 0.46–1.0, p = 0.04, 39% reduction), respectively. There was no difference in IRR between the EPA and DHA groups (p = 0.56). Both treatment groups had a significantly higher number of seizure-free days compared with the placebo group (p < 0.05).


      This study demonstrates that EPA and DHA are effective in reducing seizure frequency in patients with DRE.


      DRE (drug-resistant epilepsy), AEDs (antiepileptic drugs), DHA (docosahexaenoic acid), EPA (eicosapentaenoic acid)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Epilepsy & Behavior
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jensen F.E.
        Epilepsy in 2013: progress across the spectrum of epilepsy research.
        Nat Rev Neurol. 2014; 10: 63-64
        • Panayiotopoulos C.P.
        The new ILAE report on terminology and concepts for the organization of epilepsies: critical review and contribution.
        Epilepsia. 2012; 53: 399-404
        • Ngugi A.K.
        • Bottomley C.
        • Kleinschmidt I.
        • Sander J.W.
        • Newton C.R.
        Estimation of the burden of active and life-time epilepsy: a meta-analytic approach.
        Epilepsia. 2010; 51: 883-890
        • Kwan P.
        • Schachter S.C.
        • Brodie M.J.
        Drug-resistant epilepsy.
        N Engl J Med. 2011; 365: 919-926
        • Mitchell J.W.
        • Seri S.
        • Cavanna A.E.
        Pharmacotherapeutic and non-pharmacological options for refractory and difficult-to-treat seizures.
        J Cent Nerv Syst Dis. 2012; 4: 105-115
        • Fujita S.
        • Ikegaya Y.
        • Nishikawa M.
        • Nishiyama N.
        • Matsuki N.
        Docosahexaenoic acid improves long-term potentiation attenuated by phospholipase A(2) inhibitor in rat hippocampal slices.
        Br J Pharmacol. 2001; 132: 1417-1422
        • Vreugdenhil M.
        • Bruehl C.
        • Voskuyl R.A.
        • Kang J.X.
        • Leaf A.
        • Wadman W.J.
        Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons.
        Proc Natl Acad Sci U S A. 1996; 93: 12559-12563
        • Elinder F.
        • Liin S.I.
        Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels.
        Front Physiol. 2017; 8: 43
        • Mitchell D.C.
        • Niu S.L.
        • Litman B.J.
        Enhancement of G protein-coupled signaling by DHA phospholipids.
        Lipids. 2003; 38: 437-443
        • Zhang W.
        • Liu J.
        • Hu X.
        • Li P.
        • Leak R.K.
        • Gao Y.
        • et al.
        n3 polyunsaturated fatty acids reduce neonatal hypoxic/ischemic brain injury by promoting phosphatidylserine formation and Akt signaling.
        Stroke. 2015; 46: 2943-2950
        • Calder P.C.
        n3 fatty acids, inflammation and immunity: new mechanisms to explain old actions.
        Proc Nutr Soc. 2013; 72: 326-336
        • Patrick R.P.
        • Ames B.N.
        Vitamin D and the omega-3 fatty acids control serotonin synthesis and action, part 2: relevance for ADHD, bipolar disorder, schizophrenia, and impulsive behavior.
        FASEB J. 2015; 29: 2207-2222
        • Taha A.Y.
        • Cheon Y.
        • Ma K.
        • Rapoport S.I.
        • Rao J.S.
        Altered fatty acid concentrations in prefrontal cortex of schizophrenic patients.
        J Psychiatr Res. 2013; 47: 636-643
        • Yuen A.W.
        • Sander J.W.
        • Fluegel D.
        • Patsalos P.N.
        • Bell G.S.
        • Johnson T.
        • et al.
        Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial.
        Epilepsy Behav. 2005; 7: 253-258
        • Bromfield E.
        • Dworetzky B.
        • Hurwitz S.
        • Eluri Z.
        • Lane L.
        • Replansky S.
        • et al.
        A randomized trial of polyunsaturated fatty acids for refractory epilepsy.
        Epilepsy Behav. 2008; 12: 187-190
        • Taha A.Y.
        • Burnham W.M.
        • Auvin S.
        Polyunsaturated fatty acids and epilepsy.
        Epilepsia. 2010; 51: 1348-1358
        • Voskuyl R.A.
        • Vreugdenhil M.
        • Kang J.X.
        • Leaf A.
        Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model.
        Eur J Pharmacol. 1998; 341: 145-152
        • Xiao Y.
        • Li X.
        Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation.
        Brain Res. 1999; 846: 112-121
        • Gavzan H.
        • Sayyah M.
        • Sardari S.
        • Babapour V.
        Synergistic effect of docosahexaenoic acid on anticonvulsant activity of valproic acid and lamotrigine in animal seizure models.
        Naunyn Schmiedebergs Arch Pharmacol. 2015; 388: 1029-1038
        • DeGiorgio C.M.
        • Taha A.Y.
        Omega-3 fatty acids (ω-3 fatty acids) in epilepsy: animal models and human clinical trials.
        Expert Rev Neurother. 2016; 16: 1141-1145
        • DeGiorgio C.M.
        • Miller P.R.
        • Harper R.
        • Gornbein J.
        • Schrader L.
        • Soss J.
        • et al.
        Fish oil (n3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study.
        J Neurol Neurosurg Psychiatry. 2015; 86: 65-70
        • Schlanger S.
        • Shinitzky M.
        • Yam D.
        Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients.
        Epilepsia. 2002; 43: 103-104
        • Estruch R.
        • Ros E.
        • Salas-Salvado J.
        • Covas M.I.
        • Corella D.
        • Arós F.
        • et al.
        Primary prevention of cardiovascular disease with a Mediterranean diet.
        N Engl J Med. 2013; 368: 1279-1290
        • Purcell R.
        • Latham S.H.
        • Botham K.M.
        • Hall W.L.
        • Wheeler-Jones C.P.
        High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2alpha concentrations relative to a control high-oleic acid meal: a randomized controlled trial.
        Am J Clin Nutr. 2014; 100: 1019-1028
        • Kromhout D.
        • Giltay E.J.
        • Geleijnse J.M.
        • Alpha Omega Trial Group
        n3 fatty acids and cardiovascular events after myocardial infarction.
        N Engl J Med. 2010; 363: 2015-2026
        • Javier E.
        • Barragán-Pérez I.H.-B.
        • Huerta-Albarran R.
        Effectiveness of the use of an omega 3 and omega 6 combination (Equazen™) in paediatric patients with refractory epilepsy.
        Journal of Epilepsy and Clinical Neurophysiolog. 2011; 17: 148-153
        • Yuen A.W.
        • Flugel D.
        • Poepel A.
        • Bell G.S.
        • Peacock J.L.
        • Sander J.W.
        Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy.
        Epilepsy Behav. 2012; 23: 370-372
        • Gilby K.L.
        • Jans J.
        • McIntyre D.C.
        Chronic omega-3 supplementation in seizure-prone versus seizure-resistant rat strains: a cautionary tale.
        Neuroscience. 2009; 163: 750-758
        • Mills E.J.
        • Chan A.W.
        • Wu P.
        • Vail A.
        • Guyatt G.H.
        • Altman D.G.
        Design, analysis, and presentation of crossover trials.
        Trials. 2009; 10: 27
        • Kim H.Y.
        Novel metabolism of docosahexaenoic acid in neural cells.
        J Biol Chem. 2007; 282: 18661-18665
        • Crawford M.A.
        • Broadhurst C.L.
        • Guest M.
        • Nagar A.
        • Wang Y.
        • Ghebremeskel K.
        • et al.
        A quantum theory for the irreplaceable role of docosahexaenoic acid in neural cell signalling throughout evolution.
        Prostaglandins Leukot Essent Fatty Acids. 2013; 88: 5-13
        • Chen C.T.
        • Liu Z.
        • Ouellet M.
        • Calon F.
        • Bazinet R.P.
        Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study.
        Prostaglandins Leukot Essent Fatty Acids. 2009; 80: 157-163
        • Peet M.
        • Horrobin D.F.
        A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.
        Arch Gen Psychiatry. 2002; 59: 913-919
        • Ross B.M.
        • Seguin J.
        • Sieswerda L.E.
        Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?.
        Lipids Health Dis. 2007; 6: 21
        • El-Mowafy A.M.
        • Abdel-Dayem M.A.
        • Abdel-Aziz A.
        • El-Azab M.F.
        • Said S.A.
        Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility.
        Biochim Biophys Acta. 2011; 1811: 460-467
        • Abdel-Dayem M.A.
        • Elmarakby A.A.
        • Abdel-Aziz A.A.
        • Pye C.
        • Said S.A.
        • El-Mowafy A.M.
        Valproate-induced liver injury: modulation by the omega-3 fatty acid DHA proposes a novel anticonvulsant regimen.
        Drugs R D. 2014; 14: 85-94
        • Taha A.Y.
        • Trepanier M.O.
        • Ciobanu F.A.
        • Taha N.M.
        • Ahmed M.
        • Zeng Q.
        • et al.
        A minimum of 3 months of dietary fish oil supplementation is required to raise amygdaloid afterdischarge seizure thresholds in rats—implications for treating complex partial seizures.
        Epilepsy Behav. 2013; 27: 49-58
        • Kaplan D.I.
        • Isom L.L.
        • Petrou S.
        Role of sodium channels in epilepsy.
        Cold Spring Harb Perspect Med. 2016; 6
        • Yogeeswari P.
        • Ragavendran J.V.
        • Thirumurugan R.
        • Saxena A.
        • Sriram D.
        Ion channels as important targets for antiepileptic drug design.
        Curr Drug Targets. 2004; 5: 589-602
        • Xiao Y.F.
        • Gomez A.M.
        • Morgan J.P.
        • Lederer W.J.
        • Leaf A.
        Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes.
        Proc Natl Acad Sci U S A. 1997; 94: 4182-4187
        • Yazdi S.
        • Stein M.
        • Elinder F.
        • Andersson M.
        • Lindahl E.
        The molecular basis of polyunsaturated fatty acid interactions with the shaker voltage-gated potassium channel.
        PLoS Comput Biol. 2016; 12e1004704